The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions

Overview

Journal MedComm (2020)

Specialty Health Services

Date 2025 Mar 10

PMID 40060195

Authors

Huimin Yuan

Ruochen Xu

Senlin Li

Mengzhu Zheng

Qingyi Tong

Ming Xiang

Yonghui Zhang

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality globally, predominantly associated with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These infections drive persistent liver inflammation, culminating in cellular dysregulation, fibrosis, and cancer. Despite advancements in targeted therapies, drug resistance and the lack of reliable biomarkers for patient stratification still terribly hinder the treatment of viral HCC. To this end, the review delves into the intricate mechanisms underlying the malignant transformation of viral hepatitis to HCC, including viral integration, genomic instability, epigenetic modifications, oxidative stress, gut microbiota dysbiosis, chronic inflammation, immune escape, and abnormal signaling pathways, highlighting their complex interactions and synergies. Cutting-edge preclinical and clinical advancements in HCC management, including lifestyle modifications, drug therapies, immunotherapies, gene-based approaches, and innovative treatments, are further investigated, with particular priority given to their therapeutic potential and future applications in overcoming current limitations. By synthesizing recent scientific and clinical insights, this review aims to deepen the understanding of HCC pathogenesis in the context of chronic viral hepatitis, paving the way for novel therapeutic targets and personalized treatment strategies, ultimately improving patient outcomes.

References

Wang L, Cao D, Wang L, Zhao J, Nguyen L, Dang X . HCV-associated exosomes promote myeloid-derived suppressor cell expansion via inhibiting miR-124 to regulate T follicular cell differentiation and function. Cell Discov. 2018; 4:51. PMC: 6131392. DOI: 10.1038/s41421-018-0052-z. View

Mu Y, Ren X, Han D, Guan Y, Liu P, Cheng S . Codelivery of HBx-siRNA and Plasmid Encoding IL-12 for Inhibition of Hepatitis B Virus and Reactivation of Antiviral Immunity. Pharmaceutics. 2022; 14(7). PMC: 9318813. DOI: 10.3390/pharmaceutics14071439. View

Zhang Q, Yang L, Liu S, Zhang M, Jin Z . Interleukin-35 Suppresses Interleukin-9-Secreting CD4 T Cell Activity in Patients With Hepatitis B-Related Hepatocellular Carcinoma. Front Immunol. 2021; 12:645835. PMC: 8222719. DOI: 10.3389/fimmu.2021.645835. View

Butt S, Satnarine T, Ratna P, Sarker A, Ramesh A, Munoz C . A Systematic Review on Current Trends in the Treatment of Chronic Hepatitis B to Predict Disease Remission and Relapse. Cureus. 2023; 14(12):e32247. PMC: 9814228. DOI: 10.7759/cureus.32247. View

Atif M, Mustaan M, Falak S, Ghaffar A, Munir B . Targeting the effect of sofosbuvir on selective oncogenes expression level of hepatocellular carcinoma Ras/Raf/MEK/ERK pathway in Huh7 cell line. Saudi J Biol Sci. 2022; 29(8):103332. PMC: 9256646. DOI: 10.1016/j.sjbs.2022.103332. View

Lin X, Zuo S, Luo R, Li Y, Yu G, Zou Y . HBX-induced miR-5188 impairs FOXO1 to stimulate β-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma. Theranostics. 2019; 9(25):7583-7598. PMC: 6831466. DOI: 10.7150/thno.37717. View

. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022; 7(5):396-415. DOI: 10.1016/S2468-1253(21)00472-6. View

Shi C, Zheng Y, Pan F, Zhang F, Zhuang P, Fu W . Gallic Acid Suppressed Tumorigenesis by an LncRNA MALAT1-Wnt/β-Catenin Axis in Hepatocellular Carcinoma. Front Pharmacol. 2021; 12:708967. PMC: 8526893. DOI: 10.3389/fphar.2021.708967. View

Qian Z, Liang J, Huang R, Song W, Ying J, Bi X . HBV integrations reshaping genomic structures promote hepatocellular carcinoma. Gut. 2024; 73(7):1169-1182. PMC: 11187386. DOI: 10.1136/gutjnl-2023-330414. View

10.

Li W, Duan X, Zhu C, Liu X, Jeyarajan A, Xu M . Hepatitis B and Hepatitis C Virus Infection Promote Liver Fibrogenesis through a TGF-β1-Induced OCT4/Nanog Pathway. J Immunol. 2022; 208(3):672-684. PMC: 8770612. DOI: 10.4049/jimmunol.2001453. View

11.

Jang J, Kim H, Kim J, Lee S, Han J, Sung P . Distinct Patterns of HBV Integration and Alterations between in Tumor and Non-Tumor Tissue in Patients with Hepatocellular Carcinoma. Int J Mol Sci. 2021; 22(13). PMC: 8268258. DOI: 10.3390/ijms22137056. View

12.

Yao H, Ma S, Huang J, Si X, Yang M, Song W . Trojan-Horse Strategy Targeting the Gut-Liver Axis Modulates Gut Microbiome and Reshapes Microenvironment for Orthotopic Hepatocellular Carcinoma Therapy. Adv Sci (Weinh). 2024; 11(44):e2310002. PMC: 11600211. DOI: 10.1002/advs.202310002. View

13.

Clement S, Sobolewski C, Gomes D, Rojas A, Goossens N, Conzelmann S . Activation of the oncogenic miR-21-5p promotes HCV replication and steatosis induced by the viral core 3a protein. Liver Int. 2019; 39(7):1226-1236. DOI: 10.1111/liv.14112. View

14.

Liu X, Duan X, Holmes J, Li W, Lee S, Tu Z . A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6. Hepatology. 2018; 69(3):1004-1019. PMC: 6393205. DOI: 10.1002/hep.30266. View

15.

Chang T, Wu Y, Chi C, Su W, Chang P, Lee K . Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression. Clin Cancer Res. 2015; 21(1):201-10. DOI: 10.1158/1078-0432.CCR-13-3274. View

16.

Li P, Zhai Z, Fang J, Wang R, Li W, Wang B . PLGA micro/nanoparticle vaccination elicits non-tumor antigen specific resident memory CD8 T cell protection from hepatocellular carcinoma. Nanoscale. 2024; 16(25):12149-12162. DOI: 10.1039/d4nr00554f. View

17.

Sajid M, Liu L, Sun C . The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications. Front Immunol. 2022; 13:887186. PMC: 9165341. DOI: 10.3389/fimmu.2022.887186. View

18.

Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H . Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl):S45-57. DOI: 10.1016/j.jhep.2014.07.027. View

19.

Zheng B, Yang Y, Han Q, Yin C, Pan Z, Zhang J . STAT3 directly regulates NKp46 transcription in NK cells of HBeAg-negative CHB patients. J Leukoc Biol. 2019; 106(4):987-996. DOI: 10.1002/JLB.2A1118-421R. View

20.

Xiao W, Jiang L, Deng X, Zhu D, Pei J, Xu M . PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection. Immunol Res. 2015; 64(2):412-23. DOI: 10.1007/s12026-015-8680-y. View